Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Novello, S, Barlesi, F, Califano, R, Cufer, T, Ekman, S, Levra, M Giaj, Kerr, K, Popat, S, Reck, M, Senan, S, Simo, G V, Vansteenkiste, J, Peters, S

Volltext

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK von Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., Thomas, A., Thatcher, N., Nicolson, M.

Volltext

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial von Mansfield, A.S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., Liu, S.V., Horn, L., Wen, X., Quach, C., Yu, W., Kabbinavar, F., Lam, S., Morris, S., Califano, R.

Volltext

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 stud... von Passaro, A, Wang, J, Wang, Y, Lee, S-H, Melosky, B, Shih, J-Y, Wang, J, Azuma, K, Juan-Vidal, O, Cobo, M, Felip, E, Girard, N, Cortot, A B, Califano, R, Cappuzzo, F, Owen, S, Popat, S, Tan, J-L, Salinas, J, Tomasini, P, Gentzler, R D, William, Jr, W N, Reckamp, K L, Takahashi, T, Ganguly, S, Kowalski, D M, Bearz, A, MacKean, M, Barala, P, Bourla, A B, Girvin, A, Greger, J, Millington, D, Withelder, M, Xie, J, Sun, T, Shah, S, Diorio, B, Knoblauch, R E, Bauml, J M, Campelo, R G, Cho, B C

Volltext

Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations? von Califano, R., Gomes, F., Ackermann, C.J., Rafee, S., Tsakonas, G., Ekman, S.

Volltext

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey von Banerjee, S., Califano, R., Corral, J., de Azambuja, E., De Mattos-Arruda, L., Guarneri, V., Hutka, M., Jordan, K., Martinelli, E., Mountzios, G., Ozturk, M.A., Petrova, M., Postel-Vinay, S., Preusser, M., Qvortrup, C., Volkov, M.N.M., Tabernero, J., Olmos, D., Strijbos, M.H.

Volltext

The effect of human-mattress interface's temperature on perceived thermal comfort von Califano, R., Naddeo, A., Vink, P.

Volltext

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? von Moliner, L., Spurgeon, L., Califano, R.

Volltext

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO) von Popescu, R.A., Schäfer, R., Califano, R., Eckert, R., Coleman, R., Douillard, J.-Y., Cervantes, A., Casali, P.G., Sessa, C., Van Cutsem, E., de Vries, E., Pavlidis, N., Fumasoli, K., Wörmann, B., Samonigg, H., Cascinu, S., Cruz Hernández, J.J., Howard, A.J., Ciardiello, F., Stahel, R.A., Piccart, M.

Volltext

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions von Ortega-Franco, A., Ackermann, C., Paz-Ares, L., Califano, R.

Volltext

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression... von Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A.M., Liu, S.V., Peled, N., Pennell, N.A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H., Besse, B.

Volltext

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours von Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R

Volltext

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts von Putora, P.M., Fischer, G.F., Früh, M., Califano, R., Faivre-Finn, C., Van Houtte, P., McDonald, F., Nestle, U., Dziadziuszko, R., Le Pechoux, C., Ramella, S., Belderbos, J., Slotman, B.J., Troost, E.G.C., Peeters, S., Widder, J., Pöttgen, C., Reck, M., Blackhall, F., Cappuzzo, F., Besse, B., Novello, S., Garrido, P., Felip, E., O'Brien, M., Paz Ares, L., de Marinis, F., Westeel, V., De Ruysscher, D.

Volltext

Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts) von Tay, R.Y., Chiramel, J., Montague, E., Wilson, F., Summers, Y., Blackhall, F.H., Califano, R.

Volltext

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts von Früh, M., Panje, C.M., Reck, M., Blackhall, F., Califano, R., Cappuzzo, F., Besse, B., Novello, S., Garrido, P., Felip, E., O'Brien, M., Paz Ares, L., de Marinis, F., Westeel, V., De Ruysscher, D., Putora, P.M.

Volltext

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer von Haslett, K., Koh, P., Hudson, A., Ryder, W.D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., Faivre-Finn, C.

Volltext

Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in... von Sebastian, M., Barlesi, F., Califano, R., Mansfield, A.S., Blackhall, F.H., Flahavan, E.M., Davies, J., Arnold, P., Morris, S., Reck, M.

Volltext

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Califano, R., Hochmair, M.J., Gridelli, C., Delmonte, A., Garcia Campelo, M.R., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Ghosh, S., Tiseo, M., Haney, J., Kerstein, D., Popat, S., Camidge, D.R.

Volltext

PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial von Fennell, D., Ottensmeier, C., Califano, R., Hanna, G., Ewings, S., Hill, K., Wilding, S., Danson, S., Nye, M., Steele, N., Johnson, L., Lord, J., Middleton, C., Marwood, E., Szlosarek, P., Chan, S., Gaba, A., Darlison, L., Wells-Jordan, P., Richards, C., Poile, C., Lester, J.

Volltext

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report von Hardenberg, M.C., Patel, B., Matthews, C., Califano, R., Garcia Campelo, R., Grohe, C., Hong, M.H., Liu, G., Lu, S., de Marinis, F., Pérol, M., Soo, R.A., Stiles, B.M., Tiseo, M., Tsuboi, M.

Volltext